Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"

The aim of this study was to evaluate the survival of patients with "glioblastoma multiforme", to analyse the prognostic factors influencing the survival rate and to review recent results in the literature. Seventy five patients underwent radiation treatment between May 1998 and April 2003...

Full description

Saved in:
Bibliographic Details
Published inClinica terapeutica Vol. 159; no. 4; p. 233
Main Authors Tramacere, F, Gianicolo, E, Serinelli, M, Bambace, S, De Luca, Mc, Castagna, R, Francavilla, M C, Leone, A, Monastero, S, Fucilli, F, Pili, G, Distante, A, Portaluri, M
Format Journal Article
LanguageItalian
Published Italy 01.07.2008
Subjects
Adolescent
Adult
Age Factors
Aged
Antineoplastic Agents, Alkylating - therapeutic use
Brain Neoplasms - mortality
Brain Neoplasms - therapy
Combined Modality Therapy
Cranial Irradiation
Craniotomy
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Female
Glioblastoma - mortality
Glioblastoma - therapy
Humans
Italy - epidemiology
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Prognosis
Proportional Hazards Models
Radiotherapy Dosage
Radiotherapy, Conformal
Retrospective Studies
Survival Analysis
Young Adult
Online AccessGet more information

Cover

More Information
Summary:The aim of this study was to evaluate the survival of patients with "glioblastoma multiforme", to analyse the prognostic factors influencing the survival rate and to review recent results in the literature. Seventy five patients underwent radiation treatment between May 1998 and April 2003. Among the factors under investigation we ascertained that sex, chemotherapy, conformal treatment, surgery, and the choice of the irradiation area (whole brain or only the involved field) did not influence the survival in a statistically significant manner. Whereas age and total dose were the 95% statistically significant variables. Hazard ratio of patients older than 58 years compared to younger patients was 1.69. The death risk was 69% in older than younger patients. A greater irradiation dose improved the survival with an increase of the median survival days. The total dose lower than 6000 cGy caused an increase of 81.8% in the death risk. The median survival from the diagnosis to the death was 14.7 months (446 days) and 1-, 2- and 3- year survival rate was 69.3%, 38.4%, and 14.7% respectively. The current medical literature and our experience attests that the use of temozolomide improves the survival of these patients.
ISSN:1972-6007